missing translation for 'onlineSavingsMsg'
Learn More
Learn More
p19ARF/CDKN2A Antibody (5-C3-1), CoraFluor™ 1, Novus Biologicals™
Rat Monoclonal Antibody
Brand: Novus Biologicals NB200-174CL1
This item is not returnable.
View return policy
Description
p19ARF/CDKN2A Monoclonal antibody specifically detects p19ARF/CDKN2A in Golden Syrian Hamster (Negative),Human,Mouse samples. It is validated for Flow Cytometry,Immunohistochemistry,Immunoprecipitation,Western Blot,Immunohistochemistry (Paraffin),Immunohistochemistry (Frozen),Flow (Intracellular),CyTOF,Gene Knock-Out,Immunocytochemistry/Immunofluorescence
Specifications
| p19ARF/CDKN2A | |
| Monoclonal | |
| CoraFluor 1 | |
| alternative reading frame, ARF, ARF-INK4a, CDK4I, CDKN2A, Cyclin-dependent kinase 4 inhibitor A, cyclin-dependent kinase inhibitor 2A, cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4), cyclin-dependent kinase inhibitor 2A, isoform 3, cyclin-dependent kinase inhibitor 2A, isoforms 1/2, cyclin-dependent kinase inhibitor protein, INK4, INK4a, Ink4a/Arf, INK4a-ARF, mitochondrial smARF', MTS1, p14, p14ARF, P16, p16(INK4a), p16-INK4, p16INK4a, p16-INK4a, P19, p19<ARF>, p19ARF, Pctr1 | |
| A synthetic peptide containing amino acids 54-75 of the murine p19ARF/CDKN2A. [UniProt# Q64364] | |
| 0.1 mL | |
| ABC Transporters, Biologically Active Proteins, Cancer, Cell Biology, Cell Cycle and Replication, Chromatin Research, DNA Repair, Hypoxia, MAP Kinase Signaling, Neuroscience, p53 Pathway, Transcription Factors and Regulators, Tumor Suppressors | |
| 12578 | |
| Store at 4°C in the dark. Do not freeze. | |
| IgG2b |
| Flow Cytometry, Immunohistochemistry, Immunoprecipitation, Western Blot, Immunohistochemistry (Paraffin) | |
| 5-C3-1 | |
| PBS | |
| Rat | |
| Protein A purified | |
| RUO | |
| Primary | |
| Golden Syrian Hamster (Negative), Human, Mouse | |
| Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction